Original Investigation|Articles in Press

CT Radiomics Predict EGFR-T790M Resistance Mutation in Advanced Non-Small Cell Lung Cancer Patients After Progression on First-line EGFR-TKI

Published:March 18, 2023DOI:

      Rationale and Objectives

      We aim to explore the value of chest CT radiomics in predicting the epidermal growth factor receptor (EGFR)-T790M resistance mutation of advanced non-small cell lung cancer (NSCLC) patients after the failure of first-line EGFR-tyrosine kinase inhibitor (EGFR-TKI).

      Materials and Methods

      A total of 211 and 135 advanced NSCLC patients with tumor tissue-based (Cohort-1) or circulating tumor DNA (ctDNA)-based (Cohort-2) EGFR-T790M testing were included, respectively. Cohort-1 was used for modeling and Cohort-2 was for models’ validation. Radiomic features were extracted from tumor lesions on chest nonenhanced CT (NECT) and/or contrast-enhanced CT (CECT). We used eight feature selectors and eight classifier algorithms to establish radiomic models. Models were evaluated by area under the receiver operating characteristic curve (AUC), calibration curve, and decision curve analysis (DCA).


      CT morphological manifestations of peripheral location and pleural indentation sign were associated with EGFR-T790M. For NECT, CECT, and NECT+CECT radiomic features, the feature selector and classifier algorithms of LASSO and Stepwise logistic regression, Boruta and SVM, and LASSO and SVM were chosen to develop the optimal model, respectively (AUC: 0.844, 0.811, and 0.897). All models performed well in calibration curves and DCA. Independent validation of models in Cohort-2 revealed that both NECT and CECT models individually had limited power for predicting EGFR-T790M mutation detected by ctDNA (AUC: 0.649, 0.675), while the NECT+CECT radiomic model had a satisfactory AUC (0.760).


      This study proved the feasibility of using CT radiomic features to predict the EGFR-T790M resistance mutation, which could be helpful in guiding personalized therapeutic strategies.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Academic Radiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Siegel RL
        • Miller KD
        • Fuchs HE
        • et al.
        Cancer statistics, 2022.
        CA Cancer J Clin. 2022; 72: 7-33
        • Molina JR
        • Yang P
        • Cassivi SD
        • et al.
        Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.
        Mayo Clin Proc. 2008; 83: 584-594
        • Gahr S
        • Stoehr R
        • Geissinger E
        • et al.
        EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice.
        Br J Cancer. 2013; 109: 1821-1828
        • Shi Y
        • Au JS
        • Thongprasert S
        • et al.
        A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER).
        J Thorac Oncol. 2014; 9: 154-162
        • Kosaka T
        • Yatabe Y
        • Endoh H
        • et al.
        Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.
        Cancer Res. 2004; 64: 8919-8923
        • Inoue A
        • Kobayashi K
        • Maemondo M
        • et al.
        Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002).
        Ann Oncol. 2013; 24: 54-59
        • Sequist LV
        • Yang JC
        • Yamamoto N
        • et al.
        Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
        J Clin Oncol. 2013; 31: 3327-3334
        • Yu HA
        • Arcila ME
        • Rekhtman N
        • et al.
        Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.
        Clin Cancer Res. 2013; 19: 2240-2247
        • Wu SG
        • Liu YN
        • Tsai MF
        • et al.
        The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients.
        Oncotarget. 2016; 7: 12404-12413
        • Wang S
        • Yan B
        • Zhang Y
        • et al.
        Different characteristics and survival in non-small cell lung cancer patients with primary and acquired EGFR T790M mutation.
        Int J Cancer. 2019; 144: 2880-2886
        • Goss G
        • Tsai CM
        • Shepherd FA
        • et al.
        Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.
        Lancet Oncol. 2016; 17: 1643-1652
        • Yang JC
        • Ahn MJ
        • Kim DW
        • et al.
        Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component.
        J Clin Oncol. 2017; 35: 1288-1296
        • Mok TS
        • Wu YL
        • Ahn MJ
        • et al.
        Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer.
        N Engl J Med. 2017; 376: 629-640
        • Oxnard GR
        • Arcila ME
        • Sima CS
        • et al.
        Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation.
        Clin Cancer Res. 2011; 17: 1616-1622
        • Hata A
        • Katakami N
        • Yoshioka H
        • et al.
        Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: comparison between T790M mutation-positive and mutation-negative populations.
        Cancer. 2013; 119: 4325-4332
        • Gillies RJ
        • Kinahan PE
        • Hricak H.
        Radiomics: images are more than pictures, they are data.
        Radiology. 2016; 278: 563-577
        • Ren C
        • Zhang J
        • Qi M
        • et al.
        Machine learning based on clinico-biological features integrated (18)F-FDG PET/CT radiomics for distinguishing squamous cell carcinoma from adenocarcinoma of lung.
        European J Nuc Med Mol Imaging. 2021; 48: 1538-1549
        • Tu W
        • Sun G
        • Fan L
        • et al.
        Radiomics signature: a potential and incremental predictor for EGFR mutation status in NSCLC patients, comparison with CT morphology.
        Lung Cancer (Amsterdam, Netherlands). 2019; 132: 28-35
        • Rossi G
        • Barabino E
        • Fedeli A
        • et al.
        Radiomic detection of EGFR mutations in NSCLC.
        Cancer Res. 2021; 81: 724-731
        • Zhang G
        • Cao Y
        • Zhang J
        • et al.
        Predicting EGFR mutation status in lung adenocarcinoma: development and validation of a computed tomography-based radiomics signature.
        Am J Cancer Res. 2021; 11: 546-560
        • Zhao W
        • Wu Y
        • Xu Y
        • et al.
        The potential of radiomics nomogram in non-invasively prediction of epidermal growth factor receptor mutation status and subtypes in lung adenocarcinoma.
        Front Oncol. 2019; 9: 1485
        • Zhang M
        • Bao Y
        • Rui W
        • et al.
        Performance of (18)F-FDG PET/CT radiomics for predicting EGFR mutation status in patients with non-small cell lung cancer.
        Front Oncol. 2020; 10568857
        • Zhang L
        • Chen B
        • Liu X
        • et al.
        Quantitative biomarkers for prediction of epidermal growth factor receptor mutation in non-small cell lung cancer.
        Transl Oncol. 2018; 11: 94-101
        • Song J
        • Shi J
        • Dong D
        • et al.
        A new approach to predict progression-free survival in stage IV EGFR-mutant NSCLC patients with EGFR-TKI therapy.
        Clin Cancer Res. 2018; 24: 3583-3592
        • Yang F
        • Zhang J
        • Zhou L
        • et al.
        CT-based radiomics signatures can predict the tumor response of non-small cell lung cancer patients treated with first-line chemotherapy and targeted therapy.
        Eur Radiol. 2022; 32: 1538-1547
        • Eisenhauer EA
        • Therasse P
        • Bogaerts J
        • et al.
        New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
        Eur J Cancer. 2009; 45: 228-247
        • Dercle L
        • Fronheiser M
        • Lu L
        • et al.
        Identification of non-small cell lung cancer sensitive to systemic cancer therapies using radiomics.
        Clin Cancer Res. 2020; 26: 2151-2162
        • Wu M
        • Zhang Y
        • Zhang J
        • et al.
        A combined-radiomics approach of CT images to predict response to anti-PD-1 immunotherapy in NSCLC: a retrospective multicenter study.
        Front Oncol. 2021; 11688679
        • Tunali I
        • Tan Y
        • Gray JE
        • et al.
        Hypoxia-related radiomics and immunotherapy response: a multicohort study of non-small cell lung cancer.
        JNCI Cancer Spectr. 2021; 5 (pkab048)
        • Zwanenburg A
        • Vallières M
        • Abdalah MA
        • et al.
        The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping.
        Radiology. 2020; 295: 328-338
        • van Griethuysen JJM
        • Fedorov A
        • Parmar C
        • et al.
        Computational radiomics system to decode the radiographic phenotype.
        Cancer Res. 2017; 77: e104-e107
        • Orlhac F
        • Boughdad S
        • Philippe C
        • et al.
        A postreconstruction harmonization method for multicenter radiomic studies in PET.
        J Nuc Med. 2018; 59: 1321-1328
        • Dissaux G
        • Visvikis D
        • Da-Ano R
        • et al.
        Pretreatment (18)F-FDG PET/CT radiomics predict local recurrence in patients treated with stereotactic body radiotherapy for early-stage non-small cell lung cancer: a multicentric study.
        J Nuc Med. 2020; 61: 814-820
        • Wu Y
        • Xu L
        • Yang P
        • et al.
        Survival prediction in high-grade osteosarcoma using radiomics of diagnostic computed tomography.
        EBioMedicine. 2018; 34: 27-34
        • Yang B
        • Ji H
        • Zhong J
        • et al.
        Value of (18)F-FDG PET/CT-based radiomics nomogram to predict survival outcomes and guide personalized targeted therapy in lung adenocarcinoma with EGFR mutations.
        Front Oncol. 2020; 10567160
        • Xu L
        • Yang P
        • Liang W
        • et al.
        A radiomics approach based on support vector machine using MR images for preoperative lymph node status evaluation in intrahepatic cholangiocarcinoma.
        Theranostics. 2019; 9: 5374-5385
        • Cucchiara F
        • Del Re M
        • Valleggi S
        • et al.
        Integrating liquid biopsy and radiomics to monitor clonal heterogeneity of EGFR-positive non-small cell lung cancer.
        Front Oncol. 2020; 10593831
        • Hou D
        • Li W
        • Wang S
        • et al.
        Different clinicopathologic and computed tomography imaging characteristics of primary and acquired EGFR T790M mutations in patients with non-small-cell lung cancer.
        Cancer Manag Res. 2021; 13: 6389-6401
        • Fan Y
        • Dong Y
        • Wang H
        • et al.
        Development and externally validate MRI-based nomogram to assess EGFR and T790M mutations in patients with metastatic lung adenocarcinoma.
        Eur Radiol. 2022; 32: 6739-6751
        • He L
        • Huang Y
        • Ma Z
        • Liang C
        • Liang C
        • Liu Z.
        Effects of contrast-enhancement, reconstruction slice thickness and convolution kernel on the diagnostic performance of radiomics signature in solitary pulmonary nodule.
        Sci Rep. 2016; 6: 34921
        • Hong D
        • Xu K
        • Zhang L
        • Wan X
        • Guo Y
        Radiomics signature as a predictive factor for EGFR mutations in advanced lung adenocarcinoma.
        Front Oncol. 2020; 10: 28
        • Qiu M
        • Wang J
        • Xu Y
        • et al.
        Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: a meta-analysis.
        Cancer Epidemiol Biomarkers Prev. 2015; 24: 206-212
        • Takahama T
        • Azuma K
        • Shimokawa M
        • et al.
        Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study.
        Cancer. 2020; 126: 1940-1948
        • Lee SH
        • Kao GD
        • Feigenberg SJ
        • et al.
        Multiblock discriminant analysis of integrative (18)F-FDG-PET/CT radiomics for predicting circulating tumor cells in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy.
        Int J Radiat Oncol Biol Phys. 2021; 110: 1451-1465
        • Koo HJ
        • Kim MY
        • Park S
        • et al.
        Non-small cell lung cancer with resistance to EGFR-TKI therapy: CT characteristics of T790M mutation-positive cancer.
        Radiology. 2018; 289: 227-237
        • Rizzo S
        • Petrella F
        • Buscarino V
        • et al.
        CT radiogenomic characterization of EGFR, K-RAS, and ALK mutations in non-small cell lung cancer.
        Eur Radiol. 2016; 26: 32-42
        • Choi CM
        • Kim MY
        • Lee JC
        • Kim HJ.
        Advanced lung adenocarcinoma harboring a mutation of the epidermal growth factor receptor: CT findings after tyrosine kinase inhibitor therapy.
        Radiology. 2014; 270: 574-582
        • Matsuo N
        • Azuma K
        • Sakai K
        • et al.
        Association of EGFR Exon 19 deletion and EGFR-TKI treatment duration with frequency of T790M mutation in EGFR-mutant lung cancer patients.
        Sci Rep. 2016; 6: 36458
        • Zou B
        • Lee VHF
        • Chen L
        • Ma L
        • Wang DD
        • Yan H.
        Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations.
        Sci Rep. 2017; 7: 6595
        • Chmielecki J
        • Foo J
        • Oxnard GR
        • et al.
        Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling.
        Sci Transl Med. 2011; 3 (90ra59)
        • Hata A
        • Katakami N
        • Yoshioka H
        • et al.
        Spatiotemporal T790M heterogeneity in individual patients with EGFR-mutant non-small-cell lung cancer after acquired resistance to EGFR-TKI.
        J Thorac Oncol. 2015; 10: 1553-1559